Christmas Party @ Staburo

Christmas Party @ Staburo

Christmas Party 2020 @ Staburo

Our Christmas Party was a special one this year. Due to the current situation the event was taking place virtually. Together in groups we prepared and enjoyed delivered food packages. On the menu was a classic Christmas duck dish or a tasty vegan option followed by an orange cake with roasted apple and cinnamon mousse.

The second highlight of the evening was an online escape room game. Some of the teams completed the challenge within the time limit of one hour. The others are still searching for the person how stole the Christmas wish lists – we hope that they are successful, so that all your Christmas wishes will come true. With this in mind, we wish you relaxing Christmas holidays as well as health and happiness for the new year!

Data analysis, clinical biostatistics and more.

G-BA approves Staburo supported study on cancer treatment through stem cell transplantation

G-BA approves Staburo supported study on cancer treatment through stem cell transplantation

G-BA approves Staburo supported study on cancer treatment through stem cell transplantation

A new study in collaboration with Universitätsklinikum Hamburg-Eppendorf (UKE) and CTC North GmbH & Co. KG has been approved by the German Gemeinsamer Bundesausschuss (G-BA) on December 4. The G-BA has commissioned the UKE to research the benefits of allogeneic stem cell transplantation to treat multiple myeloma in relapsed/progressive patients. The project is led by principal investigator Prof. Dr. Nicolaus Kröger of UKE. Staburo GmbH is responsible for the statistical analysis. More information can be found in the press release of the G-BA (https://www.g-ba.de/presse/pressemitteilungen/917/).

Data analysis, clinical biostatistics and more.

Staburo presented @ workshop from the working group Pharmaceutical Research (APF)

Staburo presented @ workshop from the working group Pharmaceutical Research (APF)

Staburo presented @ workshop from the working group Pharmaceutical Research (APF)

On November 27, Staburo Managing Director Dr. Hannes Buchner gave a talk at the 74th workshop of the APF (Arbeitsgruppe Pharmazeutische Forschung) of the Deutsche Region der Internationalen Biometrischen Gesellschaft (IBS-DR). Together with Kaspar Rufibach from Roche Pharma, he presented new findings from their Oncology Estimand Working Group in the talk “Estimands update: Summary of world-wide authority interaction”. In his part of the talk, Dr. Hannes Buchner explained how to correct for treatment switching in clinical trials and how it can be included into the estimand framework.

The virtual APF workshop titled “COVID-19: Effects on statistics, methodological aspects and operational implications” was organised for biometricians working in pharmaceutical research and development, to accelerate the exchange of methods among colleagues as well as to transport mutual information on official regulations, methodological developments, and scientific events.

UPDATE 22-DEC-2020 (Thanks for sharing, Kaspar Rufibach)

For those interested to learn more: the slidedeck Hannes Buchner and Kaspar Rufibach presented is available on the webpage of the oncology estimand WG: www.oncoestimand.org (go to “Events”).

Data analysis, clinical biostatistics and more.